title: Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer.
abstract: The aim of the study was to evaluate the efficacy and tolerability of gemcitabine and uracil-tegafur (UFT) combination in patients with advanced pancreatic carcinoma, retrospectively. Thirty-one patients, including 27 with metastatic disease, were treated with gemcitabine at a dose of 1000 mg/m2 in 30 minutes on days 1 and 8, and oral UFT 300 mg/m2 on days 1-14, as the first-line regimen in advanced stage. The cycle was repeated every 21 days. A total of 116 cycles of chemotherapy were administered, with a median of 3 cycles per patient (range 1-13). The objective response rate was observed in 6 (19.3%) patients with 1 (3.2%) complete response, and 5 (16.1%) partial responses. The median response duration was 4 (range, 3-14) months. Eight (25.8%) patients had a standard deviation of more than 3 months. Median overall survival was 8 months (95% CI, 6-10 months) and median time to progression was 4.2 months (95% CI, 1-6 months). This combination was generally well tolerated. There were no life-threatening side effects. Most common toxicities were of hematologic and gastrointestinal nature. In conclusion, this regimen was well tolerated and seemed to have a moderate activity in the palliative treatment of advanced pancreatic carcinoma.
authors.affiliation: Department of Medical Oncology, Gazi University Medical School, Besevler, Ankara 06500, Turkey. ugurcos@hotmail.com
authors.forename: Ugur
authors.initials: U
authors.lastname: Coskun
authors.forename: Necati
authors.initials: N
authors.lastname: Alkis
authors.forename: Gokhan
authors.initials: G
authors.lastname: Celenkoglu
authors.forename: Süleyman
authors.initials: S
authors.lastname: Buyukberber
authors.forename: Metin
authors.initials: M
authors.lastname: Ozkan
authors.forename: Celalettin
authors.initials: C
authors.lastname: Camci
authors.forename: Aytug
authors.initials: A
authors.lastname: Uner
authors.forename: Ozlem
authors.initials: O
authors.lastname: Er
authors.forename: Ulkü Yalcintas
authors.initials: UY
authors.lastname: Aslan
authors.forename: Alper
authors.initials: A
authors.lastname: Sevinc
authors.forename: Saadet
authors.initials: S
authors.lastname: Tokluoglu
authors.forename: Banu
authors.initials: B
authors.lastname: Ozturk
authors.forename: Ramazan
authors.initials: R
authors.lastname: Yildiz
authors.forename: Mustafa
authors.initials: M
authors.lastname: Benekli
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D005641:Tegafur; D014498:Uracil; D000093542:Gemcitabine